Loading…
MINT-CIPROFLOX is a brand name for Ciprofloxacin, supplied as a tablet. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: MINT-CIPROFLOX (ciprofloxacin tablet) may be indicated for the treatment of patients with the following infections caused by susceptible strains of the indicated microorganisms: Respiratory Tract Infections Acute exacerbation of chronic bronchitis caused by: Haemophilus influenzae Moraxella catarrhalis Acute pneumonia…
Verbatim from this product's HC label. Tap a section to expand.
5 MISSED DOSE 08/2022 7 WARNINGS AND PRECAUTIONS 09/2020 TABLE OF CONTENTS Sections or subsections that are not applicable at the time of authorization are not listed. RECENT MAJOR LABEL CHANGES………………………………………………………………………………………………2 TABLE OF CONTENTS…………………………………………………………………………………………………………………2 PART I: HEALTH PROFESSIONAL INFORMATION ......................................................................
4 1. INDICATIONS ...................................................................................................................... 1 Pediatrics ...............................................................................................................................
2 Geriatrics ............................................................................................................................... 7 2. CONTRAINDICATIONS .........................................................................................................
7 3. SERIOUS WARNINGS AND PRECAUTIONS BOX..................................................................... 8 4. DOSAGE AND ADMINISTRATION ......................................................................................... 1 Dosing Considerations...........................................................................................................
2 Recommended Dose and Dosage Adjustment Adults .......................................................... 4 Administration ....................................................................................................................
5 Missed Dose ........................................................................................................................ 11 5. OVERDOSAGE ...................................................................................................................
11 6. DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING ...................................... 112 7. WARNINGS AND PRECAUTIONS ........................................................................................ 1 Special Populations .............................................................................................................
16 8. ADVERSE REACTIONS ........................................................................................................ 1 Adverse Reaction Overview ................................................................................................
). Aortic Aneurysm and Aortic Dissection Epidemiologic studies report an increased risk of aortic aneurysm and aortic dissection after intake of fluoroquinolones, particularly in the older population. , Marfan syndrome, vascular Ehlers-Danlos syndrome, Takayasu arteritis, giant cell arteritis, Behcet’s disease, hypertension, atherosclerosis).
In case of sudden severe abdominal, chest or back pain, patients should be advised to immediately consult a physician in an emergency department. , glyburide) or with insulin. In these patients, careful monitoring of blood glucose is recommended.
SEVERE CASES OF HYPOGLYCEMIA RESULTING IN COMA OR DEATH HAVE BEEN REPORTED. If a hypoglycemic reaction occurs, discontinue MINT-CIPROFLOX immediately and initiate appropriate therapy (see 8 ADVERSE REACTIONS and
09/2020 TABLE OF CONTENTS Sections or subsections that are not applicable at the time of authorization are not listed. RECENT MAJOR LABEL CHANGES………………………………………………………………………………………………2 TABLE OF CONTENTS…………………………………………………………………………………………………………………2 PART I: HEALTH PROFESSIONAL INFORMATION ......................................................................
4 1. INDICATIONS ...................................................................................................................... 1 Pediatrics ...............................................................................................................................
2 Geriatrics ............................................................................................................................... 7 2. CONTRAINDICATIONS .........................................................................................................
7 3. SERIOUS WARNINGS AND PRECAUTIONS BOX..................................................................... 8 4. DOSAGE AND ADMINISTRATION ......................................................................................... 1 Dosing Considerations...........................................................................................................
2 Recommended Dose and Dosage Adjustment Adults .......................................................... 4 Administration ....................................................................................................................
5 Missed Dose ........................................................................................................................ 11 5. OVERDOSAGE ...................................................................................................................
11 6. DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING ...................................... 112 7. WARNINGS AND PRECAUTIONS ........................................................................................ 1 Special Populations .............................................................................................................
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Ciprofloxacin in Canada.
Know a brand we are missing in Canada? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
2 Clinical Trial Adverse Reactions ........................................................................................... 3 Less Common Clinical Trial Adverse Reactions....................................................................
4 Abnormal Laboratory Findings: Hematologic, Clinical Chemistry and Other Quantitative Data...................................................................................................................................... 5 Post-Market Adverse Reactions ..........................................................................................
19 9. DRUG INTERACTIONS ........................................................................................................ 2 Drug Interactions Overview.................................................................................................
3 Drug-Behavioral Interactions .............................................................................................. 4 Drug-Drug Interactions .......................................................................................................
5 Drug-Food Interactions...................................................................................................... 6 Drug-Herb Interactions .....................................................................................................
7 Drug-Laboratory Test Interactions .................................................................................... 257 10. CLINICAL PHARMACOLOGY ...........................................................................................
1 Mechanism of Action ...................................................................................................... 3 Pharmacokinetics ............................................................................................................
267 11. STORAGE, STABILITY AND DISPOSAL .............................................................................. 323 12. SPECIAL HANDLING INSTRUCTIONS................................................................................
34 13. PHARMACEUTICAL INFORMATION ............................................................................... 334 14. CLINICAL TRIALS ............................................................................................................
2 Comparative Bioavailability Studies................................................................................ 345 15. MICROBIOLOGY ............................................................................................................
345 16. NON-CLINICAL TOXICOLOGY .......................................................................................... 389 17. SUPPORTING PRODUCT MONOGRAPHS ........................................................................ 423 PATIENT MEDICATION INFORMATION ................................................................................
434 MINT-CIPROFLOX Page 4 of 62 PART I: HEALTH PROFESSIONAL INFORMATION 1 INDICATIONS MINT-CIPROFLOX (ciprofloxacin tablet) may be indicated for the treatment of patients with the following infections caused by susceptible strains of the indicated microorganisms: Respiratory Tract Infections Acute exacerbation of chronic bronchitis caused by: Haemophilus influenzae Moraxella catarrhalis Acute pneumonia caused by: Enterobacter […]
16 8. ADVERSE REACTIONS ........................................................................................................ 1 Adverse Reaction Overview ................................................................................................
2 Clinical Trial Adverse Reactions ........................................................................................... 3 Less Common Clinical Trial Adverse Reactions....................................................................
4 Abnormal Laboratory Findings: Hematologic, Clinical Chemistry and Other Quantitative Data...................................................................................................................................... 5 Post-Market Adverse Reactions ..........................................................................................
19 9. DRUG INTERACTIONS ........................................................................................................ 2 Drug Interactions Overview.................................................................................................
3 Drug-Behavioral Interactions .............................................................................................. 4 Drug-Drug Interactions .......................................................................................................
5 Drug-Food Interactions...................................................................................................... 6 Drug-Herb Interactions .....................................................................................................
7 Drug-Laboratory Test Interactions .................................................................................... 257 10. CLINICAL PHARMACOLOGY ...........................................................................................
1 Mechanism of Action ...................................................................................................... 3 Pharmacokinetics ............................................................................................................
267 11. STORAGE, STABILITY AND DISPOSAL .............................................................................. 323 12. SPECIAL HANDLING INSTRUCTIONS................................................................................
34 13. PHARMACEUTICAL INFORMATION ............................................................................... 334 14. CLINICAL TRIALS ............................................................................................................
2 Comparative Bioavailability Studies................................................................................ 345 15. MICROBIOLOGY ............................................................................................................
345 16. NON-CLINICAL TOXICOLOGY .......................................................................................... 389 17. SUPPORTING PRODUCT MONOGRAPHS ........................................................................ 423 PATIENT MEDICATION INFORMATION ................................................................................
434 MINT-CIPROFLOX Page 4 of 62 PART I: HEALTH PROFESSIONAL INFORMATION 1 INDICATIONS MINT-CIPROFLOX (ciprofloxacin tablet) may be indicated for the treatment of patients with the following infections caused by susceptible strains of the indicated microorganisms: Respiratory Tract Infections Acute exacerbation of chronic bronchitis caused by: Haemophilus influenzae Moraxella catarrhalis Acute pneumonia caused by: Enterobacter cloacae Escherichia coli Haemophilus influenzae […]